Finally, it would be also interesting to determine whether the drugs shown or suspected to worsen NAFLD are able to reduce the expression and activity of patatin-like phospholipase domain containing 3 (PNPLA3), a lipase which appears to play a major role in the occurrence of fatty liver and its progression to steatohepatitis [259,260]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.